[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anthracycline-induced-cardiotoxicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anthracycline-induced-cardiotoxicity":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100636937","phase-2-sotagliflozin-as-prevention-of-anthracycline-related-cardiotoxicity-100636937",false,"NCT07572175","Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity","SPARTACUS Trial (Sotagliflozin as Prevention of Antracycline-Related Toxicity in Adipose, Cardiac and mUskuloSkeletal Tissues)","SPARTACUS","Inclusion Criteria\n\n* Patients ≥ 18 years\n* Newly diagnosed lymphoma\n* Scheduled to receive high-dose anthracycline (cumulative dose ≥ 300 mg\u002Fm2)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3\n\nExclusion Criteria\n\n* Prior anthracycline treatment\n* Previous malignancy requiring any chemotherapy or radiotherapy\n* Previous treatment with SGLT2i (eg due to T2DM) or SGLT1\u002F2i\n* Previous heart failure (HF patients should already be on SGLT2i as per guidelines)\n* LVEF\\\u003C40% (even in the absence of HF):\n* Pregnancy or breastfeeding\n* Standard contraindication to MRI (claustrophobia, non-MRI compatible devices)","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This project aims to determine the benefits of the dual SGLT1\u002F2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.",[27,28,29,30],"Anthracycline-induced Cardiotoxicity","Lymphoma","Chemotherapy","Cardiotoxicity",[32,33,34,35,36],"anthracycline","left ventricular dysfunction","cardiotoxicity","SGLT inhibitors","prevention","NOT_YET_RECRUITING","2026-04-30",{"date":40,"type":41},"2026-05-07","ACTUAL",{"date":43,"type":21},"2026-07",{"date":45,"type":21},"2029-10",{"name":47,"class":48},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100633584","serial-cardiac-magnetic-resonance-imaging-cmr-with-contrast-agents-and-biomarker-analysis-for-the-detection-of-cardiotoxicity-under-anthracycline-containing-cancer-therapy-100633584","NCT07528586","Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy","Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy - A Monocentric, Low Interventional Phase IV Pilot Study","CMR-Onko","Inclusion Criteria\n\n\\- Patients with a recommendation for antineoplastic therapy including at least four administrations of an anthracycline\n\nExclusion Criteria\n\n* Inability to provide informed consent\n* Prior administration of an anthracycline\n* Administration of cardiotoxic drugs within the last six months, such as:\n* High-dose cyclophosphamide (\\>1,000 mg\u002Fm² or \\>10 mg\u002Fkg)\n* HER2 inhibitors\n* VEGF inhibitors\n* BCR-ABL inhibitors\n* BRAF inhibitors\n* MEK inhibitors\n* Immune checkpoint inhibitors (CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors)\n* Planned invasive cardiac intervention during the study period\n* Cardiac involvement of an underlying disease, e.g. amyloidosis\n* Treatment with fewer than four administrations of anthracyclines\n* Treatment with a liposomal anthracycline formulation\n* Treatment in which anthracyclines are not administered in every chemotherapy cycle\n* Thoracic radiation involving the heart prior to anthracycline administration\n* Participation in another clinical study concurrently or within the last three months\n* Renal impairment with a GFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²\n* Patients in the perioperative phase of liver transplantation\n* Contraindications to cardiac magnetic resonance imaging, such as metallic implants (e.g. cardiac pacemaker)\n* Pregnancy or breastfeeding\n* Hypersensitivity or intolerance to gadolinium-based contrast agents\n* Vulnerable populations (individuals unable to protect their own interests, prisoners)",{"count":59,"type":21},93,[61],"NA","The goal of the trial is the early detection of cardiotoxicity in patients treated with anthracycline-based chemotherapy. Current diagnostics, such as troponin T, NT-pro-BNP, electrocardiogram, and echocardiography, are not able to identify early myocardial damage. Therefore, this study aims to identify early myocardial damage by using cardiac magnetic resonance imaging.\n\nThe primary endpoint of this study is the change in relaxation times in CMR before, during, and after therapy.\n\nFurthermore, the study analyzes:\n\n* other abnormal results in CMR\n* changes in troponin T and NT-pro-BNP\n* changes in global longitudinal strain in echocardiography and correlation with results of CMR\n* detection of new biomarkers in blood, urine, or stool",[30,27],[32,34,65],"cardiac magnetic resonance imaging","RECRUITING","2026-04-07",{"date":69,"type":41},"2026-04-14",{"date":71,"type":41},"2026-03-04",{"date":73,"type":21},"2030-03",{"name":75,"class":48},"Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100612487","phase-4-rosuvastatin-for-prevention-of-anthracycline-induced-cardiac-dysfunction-in-breast-cancer-patients-100612487","NCT07254221","Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients","Evaluation of Rosuvastatin Efficacy in Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients After Chemotherapy","ROSUBREAST","Inclusion Criteria:\n\n* Female individuals with ≥18 years of age\n* Documented breast cancer diagnosis based on imaging and pathology findings\n* Scheduled to receive the first time anthracycline-based chemotherapy\n\nExclusion Criteria:\n\n* Baseline LVEF \\\u003C 50%\n* Prior Statin use or Statin use is indicated based on guidelines\n* history of congestive heart failure (CHF) or cardiomyopathy\n* Pregnancy or breastfeeding\n* Unable to provide informed consent\n* Unexplained persistent elevation of transaminases (\\>3 times upper limits of normal)\n* Concomitant use of oral cyclosporine\n* Metastatic invasion of cancer to other organs\n* Previous cycles of chemotherapy\n* Any contraindication for statin use","FEMALE",{"count":86,"type":21},400,[88],"PHASE4","This study, called \"ROSUBREAST\", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based chemotherapy. A total of 400 participants will be randomly assigned to receive either rosuvastatin or placebo for 12 months. The main goal is to determine whether rosuvastatin can prevent cancer treatment-related cardiac dysfunction (CTRCD), defined as a significant drop in heart pumping function. The study will also assess changes in cardiac strain, blood biomarkers, symptoms of heart failure, quality of life, and possible side effects.",[91,92,93,27],"Anthracycline-induced Cardiac Toxicity","Breast Cancer","Anthracycline Related Cardiotoxicity in Breast Cancer",[95,96,97,98,99,100,34,101,32],"Breast cancer","rosuvastatin","statin therapy,","cancer-related treatment cardiac dysfunction","anthracycline induced cardiomyopathy","cardiac dysfunction","chemotherapy","2025-12-03",{"date":104,"type":41},"2025-12-10",{"date":106,"type":21},"2026-02-01",{"date":108,"type":21},"2028-04-21",{"name":110,"class":48},"Shiraz University of Medical Sciences",7]